Astrasana Holding AG, an internationally active manufacturer of medical and cosmetic products based on cannabinoids, has launched its new AST-Premium Line. This product line provides patients in Switzerland with hand-selected cannabis flowers of the highest quality.
Nationwide Availability
The products are already available through a network of over twenty Swiss pharmacies. The flowers have been carefully curated from Thailand and Canada, while additional cultivars originate from Astrasana’s own facility in Switzerland.
Rapid Market Growth
CEO Yves Antoniazzi reports on the dynamic market development: “The market for medical applications has only begun to unfold since the beginning of the year.” The subsidiary Bogen Pharma AG has been active in distribution since 2023, but significant growth only materialised in 2025. Antoniazzi notes monthly revenue growth of approximately 20 percent since the start of the year.
The delayed market development is attributed to the fact that patients have only been exempt from requiring a special federal authorisation since 2022, enabling simplified prescribing by physicians.
Product Range
The AST-Premium Line launches with approximately ten different cultivars, with the highest product standards and maximum patient benefit at the forefront of the selection process.
